市場調査レポート

商品コード

1700110

骨粗鬆症治療薬市場の2032年までの予測：薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、地域別の世界分析

Osteoporosis Drugs Market Forecasts to 2032 - Global Analysis by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), Calcitonin and Other Drug Classes), Route of Administration, Distribution Channel, End User and By Geography

出版日: 2025年04月03日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 595,815円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 753,742円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 911,669円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,076,775円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、骨粗鬆症治療薬の世界市場は2025年に163億米ドルを占め、予測期間中にCAGR 5.5％で成長し、2032年には238億米ドルに達する見込みです。

骨粗鬆症治療薬は、骨粗鬆症の予防、治療、管理を目的とした医薬品です。骨粗鬆症治療薬は、骨量減少を遅らせる薬（抗骨吸収薬）、または骨形成を促進する薬（同化薬）のいずれかによって作用します。一般的なものとしては、ビスフォスフォネート、選択的エストロゲン受容体モジュレーター（SERM）、カルシトニン、副甲状腺ホルモンアナログ、モノクローナル抗体などがあります。これらの薬剤は、骨折リスクの低減、骨密度の改善、骨格強度の維持に役立ちます。年齢、性別、骨折歴、骨密度などの因子に基づいて処方される骨粗鬆症治療薬は、最適な骨の健康と骨折予防のために、カルシウム、ビタミンD、生活習慣の改善と併用されることが多いです。

老年人口の増加

高齢者人口の増加は、骨粗鬆症治療薬市場成長の主要な促進要因です。加齢に伴い骨密度が低下するため骨粗鬆症の可能性が高くなり、効率的な治療に対するニーズが高まっています。高齢者のヘルスケアへのアクセスや理解が進んだ結果、市場は拡大しています。さらに、薬剤製剤の改善やオーダーメイド治療が高齢者特有の要件に対応しています。政府やヘルスケア・プロバイダーが骨の健康をより重視するようになり、患者や製薬企業にとって利益となることから、市場は着実に拡大すると予想されます。

骨粗鬆症治療薬の高コスト

骨粗鬆症治療薬の高価格は、患者の治療へのアクセスやアドヒアランスを制限し、市場の成長を著しく阻害します。特に中低所得地域では、多くの患者が経済的な負担に苦しんでおり、これが需要の低下と疾病負担の増大につながっています。さらに、高価格がヘルスケア予算や保険制度に負担をかけ、普及を阻害しています。このような経済的障壁は市場の拡大を制限し、技術革新の導入を遅らせ、患者に代替治療や効果の低い治療法を求めることを余儀なくさせる。

医薬品開発の進歩

医薬品開発の進歩は、有効性と安全性を向上させた革新的な治療法の導入により、骨粗鬆症治療薬市場を大きく牽引しています。生物学的製剤、モノクローナル抗体、新規製剤における画期的な進歩は、患者の予後を改善し、骨折リスクを低減し、骨密度を向上させています。標的治療や個別化医療における最先端の研究は、市場の可能性を拡大しています。さらに、次世代骨粗鬆症治療薬の規制当局による承認と研究開発投資の増加が市場の成長を加速させ、世界中で骨粗鬆症に苦しむ数百万人に新たな希望をもたらしています。

副作用と安全性への懸念

副作用と安全性への懸念は、骨粗鬆症治療薬市場の成長を大きく妨げています。胃腸障害、心血管系リスク、非定型骨折などの副作用は、患者のコンプライアンスや医師の処方を妨げます。安全性に関する警告や規制当局の監視は薬剤の採用をさらに制限し、売上に影響を与えます。否定的な宣伝や訴訟も消費者の信頼を損なう。こうした課題が代替治療への需要を促し、市場の拡大を制限し、製薬企業の収益源に影響を及ぼしています。

COVID-19の影響：

COVID-19の大流行は、ヘルスケア施設の閉鎖や患者の受診減少により診断と治療を遅らせ、骨粗鬆症治療薬市場を混乱させました。サプライチェーンの混乱は薬剤の入手性に影響を与え、経済の不確実性は患者の購入可能性を制限しました。しかし、閉鎖期間中に遠隔医療が普及し、骨の健康に対する意識が高まったことが市場の回復を支えました。パンデミック後、ヘルスケアサービスの再開に伴い市場は回復し、骨粗鬆症治療への需要が高まりました。

予測期間中、副甲状腺ホルモン（PTH）アナログ製剤セグメントが最大となる見込み

副甲状腺ホルモン（PTH）アナログセグメントは、骨量減少を遅らせるだけでなく骨形成を促進する能力があるため、予測期間中に最大の市場シェアを占めると予想されます。テリパラチドやアバロパラチドなどのこれらの薬剤は、特に骨折リスクの高い患者にとって有益であり、骨密度を高めて骨折リスクを低減します。認知度の向上、骨粗鬆症有病率の上昇、有利な償還政策が需要をさらに押し上げています。さらに、ドラッグデリバリーシステムにおける研究開発の継続的な取り組みと技術の進歩が、市場の存在感を高めています。

予測期間中、病院セグメントのCAGRが最も高くなる見込み

予測期間中、病院分野は最も高い成長率を示すと予測されます。これは、病院が骨密度スキャンのような高度な診断ツールを提供し、早期発見と個別化された治療計画を促進するためです。さらに、専門のヘルスケア・プロフェッショナルが患者教育と服薬コンプライアンスを強化し、転帰を改善します。骨粗鬆症の有病率の増加は、病院が包括的なケアを提供する能力と相まって、より高い薬剤需要を促進しています。さらに、製薬企業との協力関係が研究と技術革新を支援し、市場の成長をさらに拡大させています。

最大シェアの地域：

予測期間中、製剤の進歩により北米地域が最大の市場シェアを占めると予想されます。認知度の向上、政府の取り組み、医療アクセスの改善が市場拡大をさらに後押しします。製薬会社は生物製剤や同化治療で技術革新を進め、患者の転帰を向上させています。同市場は、骨折リスクを低減し、生活の質を向上させることで、公衆衛生にプラスの影響を与えています。継続的な研究開発と戦略的提携により、この分野は医療の進歩を促進し、患者とヘルスケアシステムに長期的な利益をもたらします。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域はヘルスケア投資の増加により最も高いCAGRを示すと予測されます。政府およびヘルスケアプロバイダーは骨粗鬆症管理を優先しており、先進治療へのアクセス向上につながります。薬剤製剤の革新と生物製剤の採用は、患者の転帰を向上させています。さらに、ライフスタイルの変化と都市化が骨粗鬆症の有病率を高め、需要をさらに促進しています。このような市場の拡大は、地域全体の経済成長、雇用創出、医薬品研究の進展を促進します。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

ビスホスホネート
- アレンドロネート
- リセドロネート
選択的エストロゲン受容体モジュレーター（SERM）
副甲状腺ホルモン関連タンパク質（PTHrP）類似体
副甲状腺ホルモン（PTH）類似体
RANKリガンド（RANKL）阻害剤
カルシトニン
その他の薬剤クラス

第6章世界の骨粗鬆症治療薬市場：投与経路別

経口
注射

第7章世界の骨粗鬆症治療薬市場：流通チャネル別

病院薬局
小売薬局
オンライン薬局

第8章世界の骨粗鬆症治療薬市場：エンドユーザー別

病院
クリニック
在宅ケア

第9章世界の骨粗鬆症治療薬市場：地域別

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、ジョイントベンチャー
買収と合併
新製品発売
事業拡大
その他の主要戦略

第11章企業プロファイリング

Amgen Inc.
Eli Lilly and Company
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
GlaxoSmithKline plc
Radius Health, Inc.
UCB S.A.
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche Ltd
Cipla Inc.
Daiichi Sankyo Company
Novo Nordisk A/S
Sun Pharmaceutical Industries Ltd.
AbbVie Inc.
Bayer AG
Johnson & Johnson Services Inc.
Sanofi
Bristol-Myers Squibb Company

図表

List of Tables

Table 1 Global Osteoporosis Drugs Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
Table 3 Global Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
Table 4 Global Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
Table 5 Global Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
Table 6 Global Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
Table 7 Global Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
Table 8 Global Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
Table 9 Global Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
Table 10 Global Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
Table 11 Global Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
Table 12 Global Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 13 Global Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
Table 14 Global Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
Table 15 Global Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 16 Global Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 17 Global Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 18 Global Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 19 Global Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
Table 20 Global Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
Table 21 Global Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
Table 22 Global Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 23 North America Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
Table 24 North America Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
Table 25 North America Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
Table 26 North America Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
Table 27 North America Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
Table 28 North America Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
Table 29 North America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
Table 30 North America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
Table 31 North America Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
Table 32 North America Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
Table 33 North America Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
Table 34 North America Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 35 North America Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
Table 36 North America Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
Table 37 North America Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 38 North America Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 39 North America Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 40 North America Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 41 North America Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
Table 42 North America Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
Table 43 North America Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
Table 44 North America Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 45 Europe Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
Table 46 Europe Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
Table 47 Europe Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
Table 48 Europe Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
Table 49 Europe Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
Table 50 Europe Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
Table 51 Europe Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
Table 52 Europe Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
Table 53 Europe Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
Table 54 Europe Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
Table 55 Europe Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
Table 56 Europe Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 57 Europe Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
Table 58 Europe Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
Table 59 Europe Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 60 Europe Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 61 Europe Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 62 Europe Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 63 Europe Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
Table 64 Europe Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
Table 65 Europe Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
Table 66 Europe Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 67 Asia Pacific Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
Table 68 Asia Pacific Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
Table 69 Asia Pacific Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
Table 70 Asia Pacific Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
Table 71 Asia Pacific Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
Table 72 Asia Pacific Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
Table 73 Asia Pacific Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
Table 74 Asia Pacific Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
Table 75 Asia Pacific Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
Table 76 Asia Pacific Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
Table 77 Asia Pacific Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
Table 78 Asia Pacific Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 79 Asia Pacific Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
Table 80 Asia Pacific Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
Table 81 Asia Pacific Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 82 Asia Pacific Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 83 Asia Pacific Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 84 Asia Pacific Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 85 Asia Pacific Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
Table 86 Asia Pacific Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
Table 87 Asia Pacific Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
Table 88 Asia Pacific Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 89 South America Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
Table 90 South America Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
Table 91 South America Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
Table 92 South America Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
Table 93 South America Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
Table 94 South America Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
Table 95 South America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
Table 96 South America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
Table 97 South America Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
Table 98 South America Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
Table 99 South America Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
Table 100 South America Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 101 South America Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
Table 102 South America Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
Table 103 South America Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 104 South America Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 105 South America Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 106 South America Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 107 South America Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
Table 108 South America Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
Table 109 South America Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
Table 110 South America Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
Table 111 Middle East & Africa Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
Table 112 Middle East & Africa Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
Table 113 Middle East & Africa Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
Table 114 Middle East & Africa Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
Table 115 Middle East & Africa Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
Table 116 Middle East & Africa Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
Table 117 Middle East & Africa Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
Table 118 Middle East & Africa Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
Table 119 Middle East & Africa Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
Table 120 Middle East & Africa Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
Table 121 Middle East & Africa Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
Table 122 Middle East & Africa Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 123 Middle East & Africa Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
Table 124 Middle East & Africa Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
Table 125 Middle East & Africa Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 126 Middle East & Africa Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 127 Middle East & Africa Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 128 Middle East & Africa Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 129 Middle East & Africa Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
Table 130 Middle East & Africa Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
Table 131 Middle East & Africa Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
Table 132 Middle East & Africa Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)

Product Code: SMRC29013

According to Stratistics MRC, the Global Osteoporosis Drugs Market is accounted for $16.3 billion in 2025 and is expected to reach $23.8 billion by 2032 growing at a CAGR of 5.5% during the forecast period. Osteoporosis drugs are medications designed to prevent, treat, or manage osteoporosis, a condition that weakens bones, making them fragile and prone to fractures. These drugs work by either slowing bone loss (anti-resorptive drugs) or promoting bone formation (anabolic drugs). Common classes include bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, parathyroid hormone analogs, and monoclonal antibodies. They help reduce fracture risk, improve bone density, and maintain skeletal strength. Prescribed based on factors like age, gender, fracture history, and bone mineral density, osteoporosis drugs are often combined with calcium, vitamin D, and lifestyle changes for optimal bone health and fracture prevention.

Market Dynamics:

Driver:

Rising Geriatric Population

The growing elderly population is a major driver of growth in the osteoporosis medicine market. There is a growing need for efficient treatments as osteoporosis becomes more likely as people age because of a decrease in bone density. The market is growing as a result of older individuals' increased access to and understanding of healthcare. Furthermore, improvements in medication formulations and customized therapies address the unique requirements of senior citizens. The market is expected to increase steadily as governments and healthcare providers place a greater emphasis on bone health, which will benefit patients as well as pharmaceutical businesses.

Restraint:

High Cost of Osteoporosis Drugs

The high cost of osteoporosis drugs significantly hampers market growth by limiting patient access and adherence to treatment. Many individuals, especially in low- and middle-income regions, struggle with affordability, leading to lower demand and increased disease burden. Additionally, high prices strain healthcare budgets and insurance systems, discouraging widespread adoption. This financial barrier restricts market expansion, slows innovation uptake, and forces patients to seek alternative or less effective treatment options.

Opportunity:

Advancements in Drug Development

Advancements in drug development are significantly driving the osteoporosis drugs market by introducing innovative therapies with improved efficacy and safety. Breakthroughs in biologics, monoclonal antibodies, and novel drug formulations are enhancing patient outcomes, reducing fracture risks, and improving bone density. Cutting-edge research in targeted treatments and personalized medicine is expanding the market potential. Additionally, regulatory approvals for next-generation osteoporosis drugs and increased R&D investments are accelerating market growth, offering new hope for millions suffering from osteoporosis worldwide.

Threat:

Side Effects & Safety Concerns

Side effects and safety concerns significantly hinder the growth of the osteoporosis drugs market. Adverse effects such as gastrointestinal issues, cardiovascular risks, and atypical fractures deter patient compliance and physician prescriptions. Safety warnings and regulatory scrutiny further limit drug adoption, impacting sales. Negative publicity and lawsuits also erode consumer trust. These challenges drive demand for alternative treatments, restricting market expansion and affecting pharmaceutical companies' revenue streams.

Covid-19 Impact:

The COVID-19 pandemic disrupted the osteoporosis drugs market by delaying diagnosis and treatment due to healthcare facility closures and reduced patient visits. Supply chain disruptions affected drug availability, while economic uncertainties limited patient affordability. However, increased telemedicine adoption and awareness of bone health during lockdowns supported market recovery. Post-pandemic, the market rebounded as healthcare services resumed, driving demand for osteoporosis treatments.

The parathyroid hormone (PTH) analogs segment is expected to be the largest during the forecast period

The parathyroid hormone (PTH) analogs segment is expected to account for the largest market share during the forecast period due to its ability to stimulate bone formation rather than just slowing bone loss. These drugs, such as teriparatide and abaloparatide, are particularly beneficial for high-risk fracture patients, enhancing bone density and reducing fracture risk. Increased awareness, rising osteoporosis prevalence, and favorable reimbursement policies are further boosting demand. Additionally, ongoing R&D efforts and technological advancements in drug delivery systems are expanding the market presence.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate as hospitals provide advanced diagnostic tools like bone density scans, facilitating early detection and personalized treatment plans. Additionally, specialized healthcare professionals enhance patient education and medication compliance, improving outcomes. The increasing prevalence of osteoporosis, coupled with hospitals' ability to offer comprehensive care, fosters higher drug demand. Moreover, collaborations with pharmaceutical companies support research and innovation, further expanding market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to advancements in drug formulations. Increased awareness, government initiatives, and improved healthcare access further propel market expansion. Pharmaceutical companies are innovating with biologics and anabolic treatments, enhancing patient outcomes. The market positively impacts public health by reducing fracture risks and improving quality of life. With continuous R&D and strategic collaborations, the sector fosters medical advancements, ensuring long-term benefits for patients and healthcare systems.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to increasing healthcare investments. Governments and healthcare providers are prioritizing osteoporosis management, leading to improved accessibility to advanced treatments. Innovation in drug formulations and the adoption of biologics are enhancing patient outcomes. Additionally, lifestyle changes and urbanization are increasing the prevalence of osteoporosis, further propelling demand. This market expansion fosters economic growth, job creation, and advancements in pharmaceutical research across the region.

Key players in the market

Some of the key players in Osteoporosis Drugs Market include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Radius Health, Inc., UCB S.A., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Cipla Inc., Daiichi Sankyo Company, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Bayer AG, Johnson & Johnson Services Inc., Sanofi and Bristol-Myers Squibb Company.

Key Developments:

In March 2025, Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007).

In February 2025, Summit Therapeutics Inc. announced a clinical trial collaboration with Pfizer Inc. to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.

In February 2025, Alloy Therapeutics Inc. announced its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer's ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.

Drug Classes Covered:

Bisphosphonates
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analogues
Parathyroid Hormone (PTH) Analogs
RANK Ligand (RANKL) Inhibitors
Calcitonin
Other Drug Classes

Routes of Administration Covered:

Oral
Injectable

Distribution Channels Covered:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

End Users Covered:

Hospitals
Clinics
Homecare Settings

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Osteoporosis Drugs Market, By Drug Class

5.1 Introduction
5.2 Bisphosphonates
- 5.2.1 Alendronate
- 5.2.2 Risedronate
5.3 Selective Estrogen Receptor Modulators (SERMs)
5.4 Parathyroid Hormone-Related Protein (PTHrP) Analogues
5.5 Parathyroid Hormone (PTH) Analogs
5.6 RANK Ligand (RANKL) Inhibitors
5.7 Calcitonin
5.8 Other Drug Classes

6 Global Osteoporosis Drugs Market, By Route of Administration

6.1 Introduction
6.2 Oral
6.3 Injectable

7 Global Osteoporosis Drugs Market, By Distribution Channel

7.1 Introduction
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies

8 Global Osteoporosis Drugs Market, By End User

8.1 Introduction
8.2 Hospitals
8.3 Clinics
8.4 Homecare Settings

9 Global Osteoporosis Drugs Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Amgen Inc.
11.2 Eli Lilly and Company
11.3 Merck & Co., Inc.
11.4 Novartis AG
11.5 Pfizer Inc.
11.6 GlaxoSmithKline plc
11.7 Radius Health, Inc.
11.8 UCB S.A.
11.9 Teva Pharmaceutical Industries Ltd.
11.10 F. Hoffmann-La Roche Ltd
11.11 Cipla Inc.
11.12 Daiichi Sankyo Company
11.13 Novo Nordisk A/S
11.14 Sun Pharmaceutical Industries Ltd.
11.15 AbbVie Inc.
11.16 Bayer AG
11.17 Johnson & Johnson Services Inc.
11.18 Sanofi
11.19 Bristol-Myers Squibb Company